» Articles » PMID: 26679445

Examining Differences in Opportunity and Eligibility for Cancer Clinical Trial Participation Based on Sociodemographic and Disease Characteristics

Overview
Specialties Nursing
Oncology
Date 2015 Dec 19
PMID 26679445
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose/objectives: To examine differences in opportunity and eligibility for cancer clinical trial (CCT) participation based on sociodemographic and disease characteristics.
.

Design: A matched cross-sectional study including a prospective oral questionnaire and retrospective electronic medical record (EMR) review.
.

Setting: A single hospital in a large academic National Cancer Institute-designated cancer center in Philadelphia, Pennsylvania.
.

Sample: 44 Black or Hispanic and 44 Non-Hispanic White newly diagnosed individuals matched on cancer type and age (plus or minus five years).
.

Methods: Participants answered a questionnaire to capture self-reported opportunity for CCT participation, sociodemographic information, and cancer type. With consent, the authors completed a retrospective review of the EMR to assess eligibility and collect cancer stage and performance status.
.

Main Research Variables: Opportunity and eligibility for CCT participation.
.

Findings: Most participants (78%) had no opportunity for participation and were ineligible for all available trials. No differences were noted in opportunity for participation or eligibility based on race or ethnicity. Participants with late-stage disease were more likely to have opportunity and be eligible for CCT participation (p = 0.001). Those with private insurance were less likely to have opportunity for participation (p = 0.05).
.

Conclusions: Limited trial availability and ineligibility negatively influenced opportunity for CCT participation for all populations. Levels of under-representation for CCT participation likely vary within and across sociodemographic and disease characteristics, as well as across healthcare settings.
.

Implications For Nursing: The unique roles of nurse navigators and advanced practice nurses can be leveraged to increase opportunities for CCT participation for all populations.

Citing Articles

Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials.

Riner A, Girma S, Vudatha V, Mukhopadhyay N, Skoro N, Gal T J Clin Oncol. 2022; 40(20):2193-2202.

PMID: 35316089 PMC: 9273372. DOI: 10.1200/JCO.21.02492.


Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials.

Chen Y, Valent E, van Beers E, Kuiper R, Oliva S, Haferlach T Int J Lab Hematol. 2021; 44(1):127-134.

PMID: 34448362 PMC: 9290833. DOI: 10.1111/ijlh.13691.


Before Consent: Qualitative Analysis of Deliberations of Patients With Advanced Cancer About Early-Phase Clinical Trials.

Garrett S, Matthews T, Abramson C, Koenig C, Hlubocky F, Daugherty C JCO Oncol Pract. 2019; 16(1):e56-e63.

PMID: 31603726 PMC: 6993554. DOI: 10.1200/JOP.19.00256.


Barriers to non-small cell lung cancer trial eligibility.

Hardesty J, Kanarek N Contemp Clin Trials Commun. 2018; 9:45-49.

PMID: 29696224 PMC: 5898521. DOI: 10.1016/j.conctc.2017.11.010.


The role of functional, social, and mobility dynamics in facilitating older African Americans participation in clinical research.

Shapiro E, Schamel J, Parker K, Randall L, Frew P Open Access J Clin Trials. 2017; 9:21-30.

PMID: 28804246 PMC: 5552064. DOI: 10.2147/OAJCT.S122422.

References
1.
Klamerus J, Bruinooge S, Ye X, Klamerus M, Damron D, Lansey D . The impact of insurance on access to cancer clinical trials at a comprehensive cancer center. Clin Cancer Res. 2010; 16(24):5997-6003. PMC: 3715082. DOI: 10.1158/1078-0432.CCR-10-1451. View

2.
Holmes D, Major J, Lyonga D, Alleyne R, Clayton S . Increasing minority patient participation in cancer clinical trials using oncology nurse navigation. Am J Surg. 2011; 203(4):415-22. DOI: 10.1016/j.amjsurg.2011.02.005. View

3.
Sateren W, Trimble E, Abrams J, Brawley O, Breen N, Ford L . How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002; 20(8):2109-17. DOI: 10.1200/JCO.2002.08.056. View

4.
Murthy V, Krumholz H, Gross C . Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004; 291(22):2720-6. DOI: 10.1001/jama.291.22.2720. View

5.
Ford J, Howerton M, Lai G, Gary T, Bolen S, Gibbons M . Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2007; 112(2):228-42. DOI: 10.1002/cncr.23157. View